[go: up one dir, main page]

AU2002212108A1 - Single-chain multimeric polypeptides - Google Patents

Single-chain multimeric polypeptides

Info

Publication number
AU2002212108A1
AU2002212108A1 AU2002212108A AU1210802A AU2002212108A1 AU 2002212108 A1 AU2002212108 A1 AU 2002212108A1 AU 2002212108 A AU2002212108 A AU 2002212108A AU 1210802 A AU1210802 A AU 1210802A AU 2002212108 A1 AU2002212108 A1 AU 2002212108A1
Authority
AU
Australia
Prior art keywords
multimeric polypeptides
chain multimeric
chain
polypeptides
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212108A
Inventor
Anne Dam Jensen
Torben Lauesgaard Nissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Maxygen Holdings Ltd
Original Assignee
Maxygen ApS
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen ApS, Maxygen Holdings Ltd filed Critical Maxygen ApS
Publication of AU2002212108A1 publication Critical patent/AU2002212108A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
AU2002212108A 2000-11-02 2001-11-01 Single-chain multimeric polypeptides Abandoned AU2002212108A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001647 2000-11-02
DKPA200001647 2000-11-02
PCT/DK2001/000724 WO2002036626A1 (en) 2000-11-02 2001-11-01 Single-chain multimeric polypeptides

Publications (1)

Publication Number Publication Date
AU2002212108A1 true AU2002212108A1 (en) 2002-05-15

Family

ID=8159821

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212108A Abandoned AU2002212108A1 (en) 2000-11-02 2001-11-01 Single-chain multimeric polypeptides

Country Status (3)

Country Link
EP (1) EP1334127A1 (en)
AU (1) AU2002212108A1 (en)
WO (1) WO2002036626A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
EP1425304B9 (en) * 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
KR100507796B1 (en) * 2003-04-03 2005-08-17 한미약품 주식회사 Peg-biologically active polypeptide homodimer conjugate having enhanced half life in blood and process for the preparation thereof
EP1888119B1 (en) 2005-06-01 2011-03-09 Maxygen, Inc. Pegylated g-csf polypeptides and methods of producing same
DE102005033250A1 (en) † 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Process for purifying G-CSF
CN102260343A (en) * 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 Application of recombinant human G-CSF dimer for treating nerve damage disease
CN102380090A (en) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-CSF (granulocyte-colony stimulating factor) dimmer applied to treat neutropenia
JP6196163B2 (en) 2011-03-17 2017-09-13 ミネルバ バイオテクノロジーズ コーポレーション Methods for producing pluripotent stem cells
JP2014517690A (en) * 2011-05-09 2014-07-24 ミネルバ バイオテクノロジーズ コーポレーション Genetically engineered growth factor mutants
JP5947891B2 (en) * 2011-07-25 2016-07-06 ジェネロン（シャンハイ）コーポレイション リミテッドＧｅｎｅｒｏｎ （Ｓｈａｎｇｈａｉ） Ｃｏｒｐｏｒａｔｉｏｎ Ｌｔｄ． Application of G-CSF dimer in the manufacture of pharmaceuticals to treat neurodegenerative diseases
WO2013022328A1 (en) * 2011-08-09 2013-02-14 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
CN108431018A (en) * 2015-06-12 2018-08-21 王天欣 The method of protein modification in medicinal application
CN111051512A (en) 2017-07-11 2020-04-21 辛索克斯公司 Incorporation of non-natural nucleotides and methods thereof
EP3661956A4 (en) 2017-08-03 2021-04-28 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
CN110582515A (en) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 Fusion protein comprising CD47 antibody and cytokine
CN114949240B (en) 2019-02-06 2025-09-23 新索思股份有限公司 IL-2 conjugates and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
EP0725795B1 (en) * 1994-08-12 2004-01-14 Washington University Single-chain forms of the glycoprotein hormone quartet
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2194070A1 (en) * 1995-04-26 1996-10-31 Haruhiko Yokoi Novel polypeptides
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification

Also Published As

Publication number Publication date
WO2002036626A1 (en) 2002-05-10
EP1334127A1 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
AU2001275861A1 (en) Container assembly
AU2002367404A1 (en) Redox-switchable materials
AU2002212108A1 (en) Single-chain multimeric polypeptides
AU2001239773A1 (en) Baroplastic materials
AU2001284418A1 (en) Novel polypeptide
AU2002241899A1 (en) Tip39 polypeptides
AU2002212107A1 (en) New multimeric interferon beta polypeptides
AU2001244863A1 (en) Apoptin-associating protein
AU2002239747A1 (en) Cystoskeleton-associated proteins
GB0112342D0 (en) Polypeptides
AU6983000A (en) Chimeric proteins
AU2002218199A1 (en) Truncated phosphodiesterase-7 polypeptides
AU2002240889A1 (en) Proteins that interact with betatrcp
AU2001278975A1 (en) Alpha-conotoxin peptides
GB0125093D0 (en) Multimeric proteins
AU2001278777A1 (en) Irap-binding protein
AU2001241044A1 (en) Mitf-associated proteins
AU2002224056A1 (en) Novel polypeptide
GB0018307D0 (en) Polypeptides
AU2002334199A1 (en) Multimeric proteins
AU2002225532A1 (en) Silver-dispersing polypeptides
HK1055131A (en) Anti-angiogenic polypeptides
AU2001294911A1 (en) Carbohydrate-associated proteins
AU2002244920A1 (en) Hcv-binding polypeptides
GB0113257D0 (en) Polypeptides